ZA200309894B - Solution structure of human IL-13 and uses thereof. - Google Patents
Solution structure of human IL-13 and uses thereof. Download PDFInfo
- Publication number
- ZA200309894B ZA200309894B ZA200309894A ZA200309894A ZA200309894B ZA 200309894 B ZA200309894 B ZA 200309894B ZA 200309894 A ZA200309894 A ZA 200309894A ZA 200309894 A ZA200309894 A ZA 200309894A ZA 200309894 B ZA200309894 B ZA 200309894B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino acids
- mean square
- root mean
- backbone atoms
- square deviation
- Prior art date
Links
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 title description 3
- 102000019207 human interleukin-13 Human genes 0.000 title description 3
- 102000003816 Interleukin-13 Human genes 0.000 claims description 270
- 108090000176 Interleukin-13 Proteins 0.000 claims description 270
- 239000003795 chemical substances by application Substances 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 56
- 150000001413 amino acids Chemical class 0.000 claims description 45
- 125000000539 amino acid group Chemical group 0.000 claims description 24
- 238000013461 design Methods 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 150000005829 chemical entities Chemical class 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 description 101
- 108090000978 Interleukin-4 Proteins 0.000 description 101
- 230000027455 binding Effects 0.000 description 70
- 239000000243 solution Substances 0.000 description 37
- 238000005481 NMR spectroscopy Methods 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 30
- 230000003993 interaction Effects 0.000 description 28
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 26
- 108020003175 receptors Proteins 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 23
- 239000003446 ligand Substances 0.000 description 19
- 230000000869 mutational effect Effects 0.000 description 17
- 239000000126 substance Substances 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 13
- 230000008859 change Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000012900 molecular simulation Methods 0.000 description 8
- 239000000556 agonist Substances 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000002922 simulated annealing Methods 0.000 description 6
- 238000005094 computer simulation Methods 0.000 description 5
- 239000013256 coordination polymer Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000009510 drug design Methods 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000000329 molecular dynamics simulation Methods 0.000 description 4
- 238000010995 multi-dimensional NMR spectroscopy Methods 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 239000008000 CHES buffer Substances 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 3
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 3
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 3
- KPNNXHVGOKRBEF-UHFFFAOYSA-N N-hydroxy-7-(2-naphthalenylthio)heptanamide Chemical compound C1=CC=CC2=CC(SCCCCCCC(=O)NO)=CC=C21 KPNNXHVGOKRBEF-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 238000005100 correlation spectroscopy Methods 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000003875 gradient-accelerated spectroscopy Methods 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 230000000707 stereoselective effect Effects 0.000 description 3
- 238000002424 x-ray crystallography Methods 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 238000005421 electrostatic potential Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 238000012585 nuclear overhauser effect spectroscopy experiment Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 239000011232 storage material Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000003936 working memory Effects 0.000 description 2
- KAUQJMHLAFIZDU-UHFFFAOYSA-N 6-Hydroxy-2-naphthoic acid Chemical compound C1=C(O)C=CC2=CC(C(=O)O)=CC=C21 KAUQJMHLAFIZDU-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 238000001535 HNCA Methods 0.000 description 1
- 238000001321 HNCO Methods 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101001074954 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 102100035985 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000004617 QSAR study Methods 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001472 pulsed field gradient Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000000293 three-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/20—Protein or domain folding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Theoretical Computer Science (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29660701P | 2001-06-07 | 2001-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200309894B true ZA200309894B (en) | 2004-09-29 |
Family
ID=23142750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200309894A ZA200309894B (en) | 2001-06-07 | 2003-12-22 | Solution structure of human IL-13 and uses thereof. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20030013851A1 (es) |
| EP (1) | EP1402451A4 (es) |
| JP (1) | JP2005506960A (es) |
| AR (1) | AR036333A1 (es) |
| CA (1) | CA2450147A1 (es) |
| IL (1) | IL159215A0 (es) |
| MX (1) | MXPA03011158A (es) |
| WO (1) | WO2002101629A1 (es) |
| ZA (1) | ZA200309894B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108277226A (zh) * | 2018-02-01 | 2018-07-13 | 北京市华信行生物科技有限公司 | 白细胞介素-6的编码基因及其制备方法和应用 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7774811B2 (en) * | 2004-08-26 | 2010-08-10 | Sony Corporation | Method and system for use in displaying multimedia content and status |
| CA2587903A1 (en) | 2004-11-17 | 2006-05-26 | Amgen Fremont Inc. | Fully human monoclonal antibodies to il-13 |
| SI3339445T1 (sl) | 2006-09-08 | 2020-12-31 | Abbvie Bahamas Ltd. | Beljakovine za vezavo interlevkin-13 |
| RU2009140134A (ru) * | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
| WO2010021874A2 (en) | 2008-08-20 | 2010-02-25 | Centocor Ortho Biotech Inc. | Engineered anti-il-13 antibodies, compositions, methods and uses |
| EP2850093B1 (en) | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| EP3049526B1 (en) | 2013-09-24 | 2021-02-24 | Medicenna Therapeutics, Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| CN112739713A (zh) | 2018-06-25 | 2021-04-30 | 华盛顿大学 | 有力的且选择性的白介素模拟物的从头设计 |
| US20220017588A1 (en) * | 2018-11-20 | 2022-01-20 | University Of Washington | Split interleukin mimetics and their use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
| AU5010793A (en) * | 1992-08-21 | 1994-03-15 | Schering Corporation | Human interleukin-13 |
| US6057119A (en) * | 1994-06-17 | 2000-05-02 | Vertex Pharmaceuticals, Incorporated | Crystal structure and mutants of interleukin-1β converting enzyme |
| US5614191A (en) * | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
| JP2000319298A (ja) * | 1999-03-04 | 2000-11-21 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 蛋白質複合体の結晶、構造座標、及び構造座標の使用 |
| JP2001069995A (ja) * | 1999-07-02 | 2001-03-21 | Japan Tobacco Inc | 結晶構造解析に適したｈｃｖポリメラーゼ及びその利用方法 |
| CA2388253A1 (en) * | 1999-10-14 | 2001-04-19 | Bristol-Myers Squibb Company | Crystallographic structure of the androgen receptor ligand binding domain |
| CA2389569A1 (en) * | 1999-11-16 | 2001-05-25 | Vertex Pharmaceuticals Incorporated | Crystallizable compositions comprising a caspase-7 |
| US20040137518A1 (en) * | 2002-01-31 | 2004-07-15 | Lambert Millard Hurst | CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME |
-
2002
- 2002-05-16 US US10/150,874 patent/US20030013851A1/en not_active Abandoned
- 2002-05-16 CA CA002450147A patent/CA2450147A1/en not_active Abandoned
- 2002-05-16 WO PCT/US2002/015561 patent/WO2002101629A1/en not_active Application Discontinuation
- 2002-05-16 EP EP02726880A patent/EP1402451A4/en not_active Withdrawn
- 2002-05-16 JP JP2003504310A patent/JP2005506960A/ja active Pending
- 2002-05-16 IL IL15921502A patent/IL159215A0/xx unknown
- 2002-05-16 MX MXPA03011158A patent/MXPA03011158A/es unknown
- 2002-06-07 AR ARP020102167A patent/AR036333A1/es not_active Application Discontinuation
-
2003
- 2003-12-22 ZA ZA200309894A patent/ZA200309894B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108277226A (zh) * | 2018-02-01 | 2018-07-13 | 北京市华信行生物科技有限公司 | 白细胞介素-6的编码基因及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002101629A1 (en) | 2002-12-19 |
| AR036333A1 (es) | 2004-09-01 |
| EP1402451A1 (en) | 2004-03-31 |
| JP2005506960A (ja) | 2005-03-10 |
| US20030013851A1 (en) | 2003-01-16 |
| CA2450147A1 (en) | 2002-12-19 |
| MXPA03011158A (es) | 2004-02-27 |
| EP1402451A4 (en) | 2005-01-05 |
| IL159215A0 (en) | 2004-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moy et al. | Solution structure of human IL-13 and implication for receptor binding | |
| Klaus et al. | The three-dimensional high resolution structure of human interferon α-2a determined by heteronuclear NMR spectroscopy in solution | |
| Schlessman et al. | Conformational variability in structures of the nitrogenase iron proteins from Azotobacter vinelandii and Clostridium pasteurianum | |
| US20030013851A1 (en) | Solution structure of IL-13 and uses thereof | |
| Fairbrother et al. | The solution structure of melanoma growth stimulating activity | |
| Eisenmesser et al. | Solution structure of interleukin-13 and insights into receptor engagement | |
| Gozansky et al. | Mapping the binding of the N-terminal extracellular tail of the CXCR4 receptor to stromal cell-derived factor-1α | |
| Mayer et al. | NMR solution structure and receptor peptide binding of the CC chemokine eotaxin-2 | |
| Gronenborn et al. | Modeling the three–dimensional structure of the monocyte chemo–attractant and activating protein MCAF/MCP-1 on the basis of the solution structure of interleukin-8 | |
| Spadaccini et al. | Solution structure of a sweet protein: NMR study of MNEI, a single chain monellin | |
| Tung et al. | A model of troponin-I in complex with troponin-C using hybrid experimental data: The inhibitory region is a β-hairpin | |
| Cai et al. | Solution structure of the His 12→ Cys mutant of the N‐terminal zinc binding domain of HIV‐1 integrase complexed to cadmium | |
| Spadaccini et al. | The mechanism of interaction of sweet proteins with the T1R2-T1R3 receptor: evidence from the solution structure of G16A-MNEI | |
| US20020187512A1 (en) | Crystal structure of human interleukin-22 | |
| AU2002257283A1 (en) | Solution structure of IL-13 and uses thereof | |
| Ogura et al. | Solution structure of N-terminal SH3 domain of Vav and the recognition site for Grb2 C-terminal SH3 domain | |
| Cosenza et al. | Comparative model building of interleukin-7 using interleukin-4 as a template: a structural hypothesis that displays atypical surface chemistry in helix D important for receptor activation | |
| US7460961B2 (en) | N-TRADD active site and uses thereof | |
| US7379820B2 (en) | Solution structure of RIP DD and uses thereof | |
| WO2009026172A2 (en) | New approach for designing diabetes drugs | |
| Shao et al. | CCR2 and CCR5 receptor‐binding properties of herpesvirus‐8 vMIP‐II based on sequence analysis and its solution structure | |
| EP1272845A1 (en) | SOLUTION AND CRYSTAL STRUCTURES OF ZipA AND ZipA COMPLEX AND USES THEREOF | |
| US20030186413A1 (en) | Structure of a free regulator of G-protein signaling (RGS4) and methods of identifying agonists and antagonists using same | |
| US20020045578A1 (en) | Solution structure of TNFR-1 DD and uses thereof | |
| WO2003048341A2 (en) | Cap-gly domain structure and uses thereof |